注册 English

Synthesis and α-glucosidase inhibitory activity of chrysin, diosmetin, apigenin, and luteolin derivatives

Ning Cheng ,  Wen-Bin Yi ,  Qi-Qin Wang ,  Sheng-Ming Peng ,  Xiao-Qing Zou

downloadPDF
Citation:  Ning Cheng, Wen-Bin Yi, Qi-Qin Wang, Sheng-Ming Peng, Xiao-Qing Zou. Synthesis and α-glucosidase inhibitory activity of chrysin, diosmetin, apigenin, and luteolin derivatives[J]. Chinese Chemical Letters, 2014, 25(7): 1094-1098. doi: 10.1016/j.cclet.2014.05.021 shu

Synthesis and α-glucosidase inhibitory activity of chrysin, diosmetin, apigenin, and luteolin derivatives

    • 通讯作者: Sheng-Ming Peng,
    Xiao-Qing Zou,
  • 基金项目:

    This work was financially supported by the Research Fund for the Doctoral Program of Higher Education of China (No. 20114301120004) (No. 20114301120004)

    Hunan Provincial Natural Science Foundation of China (No. 12JJ6081) (No. 12JJ6081)

    Dr.'s Start-up Foundation of Xiangtan University (No. 06KZjKZ08035) (No. 06KZjKZ08035)

    Natural Science Foundation of Xiangtan University (No. 2011XZX09). (No. 2011XZX09)

摘要: Several derivatives have been synthesized from chrysin, diosmetin, apigenin, and luteolin, which were isolated from diverse natural plants. The a-glucosidase inhibitory activity of these compounds was evaluated. The glucosidase inhibitory activity of all derivatives (IC50 < 24.396 μmol/L) was higher compared with that of the reference drug, acarbose (IC50=563.601±40.492 mmol/L), and 1-deoxynojirimycin (IC50=226.912±12.573 μmol/L). O3',7-Hexyl diosmetin (IC50=2.406 0.101 mmol/L) was the most potent inhibitor identified. These compounds showed a higher inhibitory ability compared with their precursors except the luteolin derivatives. In general, the inhibitory activity of the synthetic derivatives was enhanced with long alkyl chains at positions 3', 4' and 7 of the flavonoid.

English

  • 

    1. [1] D.R. Whiting, L. Guariguata, C. Weil, J. Shaw, IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030, Diabetes Res. Clin. Pract. 94 (2011) 311-321.[1] D.R. Whiting, L. Guariguata, C. Weil, J. Shaw, IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030, Diabetes Res. Clin. Pract. 94 (2011) 311-321.

    2. [2] S.I. Taylor, D. Accili, Y. Imai, Insulin resistance or insulin deficiency: which is the primary cause of NIDDM? Diabetes 43 (1994) 735-740.[2] S.I. Taylor, D. Accili, Y. Imai, Insulin resistance or insulin deficiency: which is the primary cause of NIDDM? Diabetes 43 (1994) 735-740.

    3. [3] D. Porte Jr., β-Cells in type II diabetes mellitus, Diabetes 40 (1991) 166-180.[3] D. Porte Jr., β-Cells in type II diabetes mellitus, Diabetes 40 (1991) 166-180.

    4. [4] A.E. Butler, J. Janson, S. Bonner-Weir, et al., β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes, Diabetes 52 (2003) 102-110.[4] A.E. Butler, J. Janson, S. Bonner-Weir, et al., β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes, Diabetes 52 (2003) 102-110.

    5. [5] P.C. Tang, Z.G. Lin, Y. Wang, et al., Design and synthesis of DPP-4 inhibitor for the treatment of type 2 diabetes, Chin. Chem. Lett. 21 (2010) 253-256.[5] P.C. Tang, Z.G. Lin, Y. Wang, et al., Design and synthesis of DPP-4 inhibitor for the treatment of type 2 diabetes, Chin. Chem. Lett. 21 (2010) 253-256.

    6. [6] Y.H. Wu, Synthesis of (S)-2-ethoxy-3-phenylpropanoic acid derivatives and their insulin-sensitizing activity, Chin. J. Chem. 25 (2007) 265-267.[6] Y.H. Wu, Synthesis of (S)-2-ethoxy-3-phenylpropanoic acid derivatives and their insulin-sensitizing activity, Chin. J. Chem. 25 (2007) 265-267.

    7. [7] A.H. Samad, T.S.T. Willing, K.G.M. Alberti, R. Taylor, Effects of BAYm 1099, new aglucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo, Diabetes Care 11 (1988) 337-344.[7] A.H. Samad, T.S.T. Willing, K.G.M. Alberti, R. Taylor, Effects of BAYm 1099, new aglucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo, Diabetes Care 11 (1988) 337-344.

    8. [8] N. Asano, Glycosidase inhibitors: update and perspectives on practical use, Glycobiology 13 (2003) 93R-104R.[8] N. Asano, Glycosidase inhibitors: update and perspectives on practical use, Glycobiology 13 (2003) 93R-104R.

    9. [9] K. O'Dea, J. Turton, Optimum effectiveness of intestinal alpha-glucosidase inhibitors: importance of uniform distribution through a meal, Am. J. Clin. Nutr. 41 (1985) 511-516.[9] K. O'Dea, J. Turton, Optimum effectiveness of intestinal alpha-glucosidase inhibitors: importance of uniform distribution through a meal, Am. J. Clin. Nutr. 41 (1985) 511-516.

    10. [10] P. Lefebvre, A. Scheen, The use of acarbose in the prevention and treatment of hypoglycaemia, Eur. J. Clin. Invest. 24 (1994) 40-44.[10] P. Lefebvre, A. Scheen, The use of acarbose in the prevention and treatment of hypoglycaemia, Eur. J. Clin. Invest. 24 (1994) 40-44.

    11. [11] L.J. Scott, C.M. Spencer, Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus, Drugs 59 (2000) 521-549.[11] L.J. Scott, C.M. Spencer, Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus, Drugs 59 (2000) 521-549.

    12. [12] L.K. Campbell, D.E. Baker, R.K. Campbell, Miglitol: assessment of its role in the treatment of patients with diabetes mellitus, Ann. Pharmacother. 34 (2000) 1291-1301.[12] L.K. Campbell, D.E. Baker, R.K. Campbell, Miglitol: assessment of its role in the treatment of patients with diabetes mellitus, Ann. Pharmacother. 34 (2000) 1291-1301.

    13. [13] A.J. Krentz, C.J. Bailey, Oral antidiabetic agents, Drugs 65 (2005) 385-411.[13] A.J. Krentz, C.J. Bailey, Oral antidiabetic agents, Drugs 65 (2005) 385-411.

    14. [14] D. Nathan, J. Buse, M. Davidson, et al., Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy, Diabetologia 49 (2006) 1711-1721.[14] D. Nathan, J. Buse, M. Davidson, et al., Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy, Diabetologia 49 (2006) 1711-1721.

    15. [15] S.H. Hsiao, L.H. Liao, P.N. Cheng, T.J. Wu, Hepatotoxicity associated with acarbose therapy, Ann. Pharmacother. 40 (2006) 151-154.[15] S.H. Hsiao, L.H. Liao, P.N. Cheng, T.J. Wu, Hepatotoxicity associated with acarbose therapy, Ann. Pharmacother. 40 (2006) 151-154.

    16. [16] Z.Y. Du, R.R. Liu, W.Y. Shao, et al., α-Glucosidase inhibition of natural curcuminoids and curcumin analogs, Eur. J. Med. Chem. 41 (2006) 213-218.[16] Z.Y. Du, R.R. Liu, W.Y. Shao, et al., α-Glucosidase inhibition of natural curcuminoids and curcumin analogs, Eur. J. Med. Chem. 41 (2006) 213-218.

    17. [17] E.B. de Melo, A. da Silveira Gomes, I. Carvalho, α-and β-glucosidase inhibitors: chemical structure and biological activity, Tetrahedron 62 (2006) 10277-10302.[17] E.B. de Melo, A. da Silveira Gomes, I. Carvalho, α-and β-glucosidase inhibitors: chemical structure and biological activity, Tetrahedron 62 (2006) 10277-10302.

    18. [18] Y.I. Kwon, E. Apostolidis, K. Shetty, In vitro studies of eggplant (Solanum melongena) phenolics as inhibitors of key enzymes relevant for type 2 diabetes and hypertension, Bioresour. Technol. 99 (2008) 2981-2988.[18] Y.I. Kwon, E. Apostolidis, K. Shetty, In vitro studies of eggplant (Solanum melongena) phenolics as inhibitors of key enzymes relevant for type 2 diabetes and hypertension, Bioresour. Technol. 99 (2008) 2981-2988.

    19. [19] R. Tundis, M. Loizzo, F. Menichini, Natural products as-amylase and-glucosidase inhibitors and their hypoglycaemic potential in the treatment of diabetes: an update, Mini-Rev. Med. Chem. 10 (2010) 315-331.[19] R. Tundis, M. Loizzo, F. Menichini, Natural products as-amylase and-glucosidase inhibitors and their hypoglycaemic potential in the treatment of diabetes: an update, Mini-Rev. Med. Chem. 10 (2010) 315-331.

    20. [20] L.G. Ranilla, Y.I. Kwon, E. Apostolidis, K. Shetty, Phenolic compounds, antioxidant activity and in vitro inhibitory potential against key enzymes relevant for hyperglycemia and hypertension of commonly used medicinal plants, herbs and spices in Latin America, Bioresour. Technol. 101 (2010) 4676-4689.[20] L.G. Ranilla, Y.I. Kwon, E. Apostolidis, K. Shetty, Phenolic compounds, antioxidant activity and in vitro inhibitory potential against key enzymes relevant for hyperglycemia and hypertension of commonly used medicinal plants, herbs and spices in Latin America, Bioresour. Technol. 101 (2010) 4676-4689.

    21. [21] M. Liu, W. Zhang, J. Wei, X. Lin, Synthesis and α-glucosidase inhibitory mechanisms of bis(2, 3-dibromo-4, 5-dihydroxybenzyl) ether, a potential marine bromophenol α-glucosidase inhibitor, Mar. Drugs 9 (2011) 1554-1565.[21] M. Liu, W. Zhang, J. Wei, X. Lin, Synthesis and α-glucosidase inhibitory mechanisms of bis(2, 3-dibromo-4, 5-dihydroxybenzyl) ether, a potential marine bromophenol α-glucosidase inhibitor, Mar. Drugs 9 (2011) 1554-1565.

    22. [22] R.R. Rao, A.K. Tiwari, P.P. Reddy, et al., Synthesis of antihyperglycemic, α-glucosidase inhibitory, and DPPH free radical scavenging furanochalcones, Med. Chem. Res. 21 (2012) 760-774.[22] R.R. Rao, A.K. Tiwari, P.P. Reddy, et al., Synthesis of antihyperglycemic, α-glucosidase inhibitory, and DPPH free radical scavenging furanochalcones, Med. Chem. Res. 21 (2012) 760-774.

    23. [23] J.D. Xu, L.W. Zhang, Y.F. Liu, Synthesis and antioxidant activities of flavonoids derivatives, troxerutin and 3', 4', 7-triacetoxyethoxyquercetin, Chin. Chem. Lett. 24 (2013) 223-226.[23] J.D. Xu, L.W. Zhang, Y.F. Liu, Synthesis and antioxidant activities of flavonoids derivatives, troxerutin and 3', 4', 7-triacetoxyethoxyquercetin, Chin. Chem. Lett. 24 (2013) 223-226.

    24. [24] J.B. Zheng, H.F. Zhang, H. Gao, Investigation on electrochemical behavior and scavenging superoxide anion ability of chrysin at mercury electrode, Chin. J. Chem. 23 (2005) 1042-1046.[24] J.B. Zheng, H.F. Zhang, H. Gao, Investigation on electrochemical behavior and scavenging superoxide anion ability of chrysin at mercury electrode, Chin. J. Chem. 23 (2005) 1042-1046.

    25. [25] H.D. Ly, S.G. Withers, Mutagenesis of glycosidases, Annu. Rev. Biochem. 68 (1999) 487-522.[25] H.D. Ly, S.G. Withers, Mutagenesis of glycosidases, Annu. Rev. Biochem. 68 (1999) 487-522.

    26. [26] T. Schewe, Y. Steffen, H. Sies, How do dietary flavanols improve vascular function? A position paper, Arch. Biochem. Biophys. 476 (2008) 102-106.[26] T. Schewe, Y. Steffen, H. Sies, How do dietary flavanols improve vascular function? A position paper, Arch. Biochem. Biophys. 476 (2008) 102-106.

    27. [27] M.N. Clifford, Chlorogenic acids and other cinnamates -nature, occurrence and dietary burden, J. Sci. Food Agric. 79 (1999) 362-372.[27] M.N. Clifford, Chlorogenic acids and other cinnamates -nature, occurrence and dietary burden, J. Sci. Food Agric. 79 (1999) 362-372.

    28. [28] M. Richelle, I. Tavazzi, E. Offord, Comparison of the antioxidant activity of commonly consumed polyphenolic beverages (coffee, cocoa, and tea) prepared per cup serving, J. Agric. Food Chem. 49 (2001) 3438-3442.[28] M. Richelle, I. Tavazzi, E. Offord, Comparison of the antioxidant activity of commonly consumed polyphenolic beverages (coffee, cocoa, and tea) prepared per cup serving, J. Agric. Food Chem. 49 (2001) 3438-3442.

    29. [29] A. Crozier, I.B. Jaganath, M.N. Clifford, Dietary phenolics: chemistry, bioavailability and effects on health, Nat. Prod. Rep. 26 (2009) 1001-1043.[29] A. Crozier, I.B. Jaganath, M.N. Clifford, Dietary phenolics: chemistry, bioavailability and effects on health, Nat. Prod. Rep. 26 (2009) 1001-1043.

    30. [30] Q.Q. Wang, N. Cheng, X.W. Zheng, S.M. Peng, X.Q. Zou, Synthesis of organic nitrates of luteolin as a novel class of potent aldose reductase inhibitors, Bioorg. Med. Chem. 21 (2013) 4301-4310.[30] Q.Q. Wang, N. Cheng, X.W. Zheng, S.M. Peng, X.Q. Zou, Synthesis of organic nitrates of luteolin as a novel class of potent aldose reductase inhibitors, Bioorg. Med. Chem. 21 (2013) 4301-4310.

    31. [31] J.H. Cui, D. Hu, X. Zhang, Z. Jing, et al., Design and synthesis of new 7, 8-dimethoxya-naphthoflavones as CYP1A1 inhibitors, Chin. Chem. Lett. 24 (2013) 215-218.[31] J.H. Cui, D. Hu, X. Zhang, Z. Jing, et al., Design and synthesis of new 7, 8-dimethoxya-naphthoflavones as CYP1A1 inhibitors, Chin. Chem. Lett. 24 (2013) 215-218.

    32. [32] K. Hanhineva, R. Törrönen, I. Bondia-Pons, et al., Impact of dietary polyphenols on carbohydrate metabolism, Int. J. Mol. Sci. 11 (2010) 1365-1402.[32] K. Hanhineva, R. Törrönen, I. Bondia-Pons, et al., Impact of dietary polyphenols on carbohydrate metabolism, Int. J. Mol. Sci. 11 (2010) 1365-1402.

    33. [33] T. Nishioka, J. Kawabata, Y. Aoyama, Baicalein, an a-glucosidase inhibitor from Scutellaria baicalensis, J. Nat. Prod. 61 (1998) 1413-1415.[33] T. Nishioka, J. Kawabata, Y. Aoyama, Baicalein, an a-glucosidase inhibitor from Scutellaria baicalensis, J. Nat. Prod. 61 (1998) 1413-1415.

    34. [34] H.W. Ryu, B.W. Lee, M.J. Curtis-Long, et al., Polyphenols from Broussonetia papyrifera displaying potent a-glucosidase inhibition, J. Agric. Food Chem. 58 (2009) 202-208.[34] H.W. Ryu, B.W. Lee, M.J. Curtis-Long, et al., Polyphenols from Broussonetia papyrifera displaying potent a-glucosidase inhibition, J. Agric. Food Chem. 58 (2009) 202-208.

    35. [35] K. Tadera, Y. Minami, K. Takamatsu, T. Matsuoka, Inhibition of α-glucosidase and a-amylase by flavonoids, J. Nutr. Sci. Vitaminol. (Tokyo) 52 (2006) 149-153.[35] K. Tadera, Y. Minami, K. Takamatsu, T. Matsuoka, Inhibition of α-glucosidase and a-amylase by flavonoids, J. Nutr. Sci. Vitaminol. (Tokyo) 52 (2006) 149-153.

    36. [36] W. Hakamata, I. Nakanishi, Y. Masuda, et al., Planar catechin analogues with alkyl side chains: a potent antioxidant and an α-glucosidase inhibitor, J. Am. Chem. Soc. 128 (2006) 6524-6525.[36] W. Hakamata, I. Nakanishi, Y. Masuda, et al., Planar catechin analogues with alkyl side chains: a potent antioxidant and an α-glucosidase inhibitor, J. Am. Chem. Soc. 128 (2006) 6524-6525.

    37. [37] J.S. Shin, K.S. Kim, M.B. Kim, J.H. Jeong, B.K. Kim, Synthesis and hypoglycemic effect of chrysin derivatives, Bioorg. Med. Chem. Lett. 9 (1999) 869-874.[37] J.S. Shin, K.S. Kim, M.B. Kim, J.H. Jeong, B.K. Kim, Synthesis and hypoglycemic effect of chrysin derivatives, Bioorg. Med. Chem. Lett. 9 (1999) 869-874.

    38. [38] D.C. Wan, J.J. Yuan, Z.L. Yang, et al., Facile O-alkylation of highly hydrophilic hyperbranched polyglycerol, Chin. Chem. Lett. 18 (2007) 192-194.[38] D.C. Wan, J.J. Yuan, Z.L. Yang, et al., Facile O-alkylation of highly hydrophilic hyperbranched polyglycerol, Chin. Chem. Lett. 18 (2007) 192-194.

    39. [39] Y. Kashima, H. Yamaki, T. Suzuki, M. Miyazawa, Structure-activity relationships of bergenin derivatives effect on α-glucosidase inhibition, J. Enzyme Inhib. Med. Chem. 28 (2013) 1162-1170.[39] Y. Kashima, H. Yamaki, T. Suzuki, M. Miyazawa, Structure-activity relationships of bergenin derivatives effect on α-glucosidase inhibition, J. Enzyme Inhib. Med. Chem. 28 (2013) 1162-1170.

    40. [40] Y.Q. Li, F.C. Zhou, F. Gao, J.S. Bian, F. Shan, Comparative evaluation of quercetin, isoquercetin and rutin as inhibitors of α-glucosidase, J. Agric. Food. Chem. 57 (2009) 11463-11468.[40] Y.Q. Li, F.C. Zhou, F. Gao, J.S. Bian, F. Shan, Comparative evaluation of quercetin, isoquercetin and rutin as inhibitors of α-glucosidase, J. Agric. Food. Chem. 57 (2009) 11463-11468.

    41. [41] W. Li, K. Wei, H. Fu, K. Koike, Structure and absolute configuration of clerodane diterpene glycosides and a rearranged cadinane sesquiterpene glycoside from the stems of Tinospora sinensis, J. Nat. Prod. 70 (2007) 1971-1976.[41] W. Li, K. Wei, H. Fu, K. Koike, Structure and absolute configuration of clerodane diterpene glycosides and a rearranged cadinane sesquiterpene glycoside from the stems of Tinospora sinensis, J. Nat. Prod. 70 (2007) 1971-1976.

    42. [42] S. Adisakwattana, P. Charoenlertkul, S. Yibchok-anun, α-Glucosidase inhibitory activity of cyanidin-3-galactoside and synergistic effect with acarbose, J. Enzyme Inhib. Med. Chem. 24 (2009) 65-69.[42] S. Adisakwattana, P. Charoenlertkul, S. Yibchok-anun, α-Glucosidase inhibitory activity of cyanidin-3-galactoside and synergistic effect with acarbose, J. Enzyme Inhib. Med. Chem. 24 (2009) 65-69.

    43. [43] C.M. Ma, M. Hattori, M. Daneshtalab, L. Wang, Chlorogenic acid derivatives with alkyl chains of different lengths and orientations: potent α-glucosidase inhibitors, J. Med. Chem. 51 (2008) 6188-6194.[43] C.M. Ma, M. Hattori, M. Daneshtalab, L. Wang, Chlorogenic acid derivatives with alkyl chains of different lengths and orientations: potent α-glucosidase inhibitors, J. Med. Chem. 51 (2008) 6188-6194.

    44. [44] G.L. Li, J.Y. He, A. Zhang, et al., Toward potent α-glucosidase inhibitors based on xanthones: a closer look into the structure-activity correlations, Eur. J. Med. Chem. 46 (2011) 4050-4055.[44] G.L. Li, J.Y. He, A. Zhang, et al., Toward potent α-glucosidase inhibitors based on xanthones: a closer look into the structure-activity correlations, Eur. J. Med. Chem. 46 (2011) 4050-4055.

    45. [45] T.D. Heightman, A.T. Vasella, Recent insights into inhibition, structure, and mechanism of configuration-retaining glycosidases, Angew. Chem. Int. Ed. 38 (1999) 750-770.[45] T.D. Heightman, A.T. Vasella, Recent insights into inhibition, structure, and mechanism of configuration-retaining glycosidases, Angew. Chem. Int. Ed. 38 (1999) 750-770.

    46. [46] A. Vasella, G.J. Davies, M. Böhm, Glycosidase mechanisms, Curr. Opin. Chem. Biol. 6 (2002) 619-629.[46] A. Vasella, G.J. Davies, M. Böhm, Glycosidase mechanisms, Curr. Opin. Chem. Biol. 6 (2002) 619-629.

    47. [47] D.L. Zechel, S.G. Withers, Glycosidase mechanisms: anatomy of a finely tuned catalyst, Acc. Chem. Res. 33 (2000) 11-18.[47] D.L. Zechel, S.G. Withers, Glycosidase mechanisms: anatomy of a finely tuned catalyst, Acc. Chem. Res. 33 (2000) 11-18.

    48. [48] H. Gao, T. Nishioka, J. Kawabata, T. Kasai, Structure-activity relationships for aglucosidase inhibition of baicalein, 5, 6, 7-trihydroxyflavone: the effect of A-ring substitution, Biosci. Biotechnol. Biochem. 68 (2004) 369-375.[48] H. Gao, T. Nishioka, J. Kawabata, T. Kasai, Structure-activity relationships for aglucosidase inhibition of baicalein, 5, 6, 7-trihydroxyflavone: the effect of A-ring substitution, Biosci. Biotechnol. Biochem. 68 (2004) 369-375.

    49. [49] V. Kumar, S. Kumar, P. Rani, Pharmacophore modeling and 3D-QSAR studies on flavonoids as a-glucosidase inhibitors, Der Pharma Chemica 2 (2010) 324-335.[49] V. Kumar, S. Kumar, P. Rani, Pharmacophore modeling and 3D-QSAR studies on flavonoids as a-glucosidase inhibitors, Der Pharma Chemica 2 (2010) 324-335.

  • 加载中
WeChat 扫一扫看文章
计量
  • PDF下载量:  0
  • 文章访问数:  1466
  • HTML全文浏览量:  27
文章相关
  • 收稿日期:  2014-03-13
  • 网络出版日期:  2014-04-30
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

/

返回文章

All Rights Reserved by the Chinese Chemical Society   中国化学会 版权所有 京ICP备05002797号

本系统由北京仁和汇智信息技术有限公司开发    技术支持: info@rhhz.net